EBITDA at other companies
Other financials
Where this comes from
Calculated from Perspective Therapeutics’s reported figures.
The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Perspective Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Perspective Therapeutics's EBITDA?
- Perspective Therapeutics (CATX) reported EBITDA of -$27.16M in Q1 2026.
- How has Perspective Therapeutics's EBITDA changed year-over-year?
- Perspective Therapeutics's EBITDA decreased by 28.7% year-over-year, from -$21.1M to -$27.16M.
- What is the long-term trend for Perspective Therapeutics's EBITDA?
- Over 2 years (2023 to 2025), Perspective Therapeutics's EBITDA has grown at a 66.2% compound annual growth rate (CAGR), from -$39.96M to -$110.31M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.